80 results on '"Berger W"'
Search Results
2. Triapine-mediated ABCB1 induction via PKC induces widespread therapy unresponsiveness but is not underlying acquired triapine resistance
3. THE ROLE OF PEANUT COMPONENT ARA H 8 SCREENING FOR PEANUT IMMUNOTHERAPY CLINICAL TRIALS
4. Resource recovery from urban stock, the example of cadmium and tellurium from thin film module recycling
5. Leaching experiments on the release of heavy metals and PAH from soil and waste materials
6. Comparison of stir bar sorptive extraction (SBSE) and liquid–liquid extraction (LLE) for the analysis of polycyclic aromatic hydrocarbons (PAH) in complex aqueous matrices
7. UP16 - Genetic and pharmacological characterization of patient-derived bladder cancer cell models for novel therapeutic target identification
8. Excess photo-carriers and cumulative Auger effects in GaAs–Ge quantum wells for high efficiency p–i (qw)–n solar cells
9. L’inhibiteur de la tyrosine kinase de Bruton, rémibrutinib (LOU064), dans l’urticaire chronique spontanée: principaux résultats de l’étude de phase 2b
10. Kava-Kava extract LI 150 is as effective as Opipramol and Buspirone in Generalised Anxiety Disorder – An 8-week randomized, double-blind multi-centre clinical trial in 129 out-patients
11. MA06.04 FGF5 Expression in Malignant Pleural Mesothelioma: Impact on Cell Growth, Cisplatin Resistance and Patient Survival
12. Changes in mechanical muscle fibre properties may contribute to spastic muscle hypertonia
13. A Calculated Risk: Systematic Review and Metaanalysis of the Conditional Risk for Posttraumatic Stress Disorder (PTSD) in the Brazilian General Population
14. P.846 Genetic haplotype of the glymphatic-associated water channel aquaporin 4 modulates slow waves in human non-rapid eye movement sleep
15. P2.06-21 Low Intratumoral Platinum Concentration is Associated with Unfavorable Clinical Outcome in Malignant Pleural Mesothelioma
16. P.2.034 - Genotype-dependent deterioration of sustained attention by the COMT inhibitor tolcapone after sleep deprivation
17. MA 19.07 Does Loss of Smad7 Lead to Increased Aggressiveness of Malignant Pleural Mesothelioma?
18. Correlation of quantitative 5-ALA induced fluorescence intensity with histopathological parameters of malignancy in newly diagnosed gliomas
19. 412 - MONDTI: Molecular characterisation platform for identifying actionable mutations in advanced or metastatic cancers
20. P325 Time to a clinically-meaningful response with mp-azeflu in children with seasonal allergic rhinitis (SAR)
21. P324 Efficacy of MP-AzeFlu in children with seasonal allergic rhinitis: importance of child symptom assessment
22. 508P - Cetuximab biweekly (q2w) plus mFOLFOX6 as 1st line therapy in patients (pts) with KRAS wild-type (wt) (exon 2) metastatic colorectal cancer (mCRC) – Primary endpoint and subgroup analysis of the CEBIFOX trial
23. Enniatin B and beauvericin distribution and persistence in mice after intraperitoneal administration
24. 546 ER Stress is an Additional Molecular Target for Triapine and Its Dimethylated Derivative
25. 1062 Selection for Trabectedin Resistance Induces Stable and p53-independent Hypersensitivity Against Cisplatin in Human Colon Cancer Cells
26. 984 Methylation of the Oxaliplatin Cyclohexane Ring Leads to Reduced Side-effects and Enhanced Anticancer Activity
27. 966 Rapid Disturbance of the Intracellular Redox Balance Predicts Sensitivity to the Preclinical Anticancer Ruthenium Compound KP1339
28. 838 The FGF Axis in Melanoma – FGF5 as Novel Player and Combination Strategies for Effective Targeting
29. 831 Telomerase Activity Has Prognostic Quality for Glioblastoma Patients Preferentially of Younger Age
30. 427 The Major Vault Protein (MVP) Mediates Starvation Resistance of Human Glioblastoma Cells Via Deregulation of the PI3kinase Pathway
31. 447 Stereoisomerism significantly impacts on the anticancer activity of novel oxaliplatin analogues in vitro and in vivo
32. 339 Fibroblast growth factor receptor 4 (FGFR4) G388R polymorphism in colorectal cancer
33. 188 Synergistic activity of the novel apoptosis-inducing compound KP1339 with the tyrosine kinase inhibitor sorafenib in cancer cell lines of diverse origin
34. 114 The dual PI3K/mTOR blocker NVP-BEZ235 sensitizes cancer cells against irreversible ErbB inhibitors
35. 206 Downstream signaling pathways determine resistance of cancer cells against novel irreversible ErbB-targeting drugs
36. PMS6 HEALTH ASSESSMENT QUESTIONNAIRE-DISABILITY INDEX (HAQ-DI) SCORES IN PATIENTS WITH RHEUMATOID ARTHRITIS (RA) TREATED WITH TOCILIZUMAB PLUS CONVENTIONAL ANTI-RHEUMATIC DRUGS
37. Targeting the sodium pump α1 subunit in experimental glioblastomas increases the anti-tumor effects of Temodal and of Avastin-Irinotecan regimens
38. Temozolomide treatment of experimental glioblastomas reveals the ugly face of caveolin-1
39. Chronic temozolomide treatment of human glioblastoma cell lines from astrocytic origin increases their aggressiveness in vivo
40. Narciclasine, a plant growth modulator showing anti-glioblastoma activity in vitro and in vivo in human preclinical glioblastoma models
41. Temozolomide displays antimigratory effects in human glioblastoma cells mediated through neuregulin-1 down-regulation
42. Un traitement chronique in vitro de lignées humaines de glioblastomes d’origine astrocytaire par le témozolomide augmente leur agressivité in vivo et induit leur résistance au témozolomide
43. 590 POSTER Molecular and antiproliferative effects of inhibitors of fatty acid synthase and of ErbB receptors in ovarian cancer cells
44. 559 POSTER The role of the ErbB3/PI3K/AKT pathway in determining breast cancer cell sensitivity against the irreversible dual EGFR/ErbB2 inhibitor EKB-569
45. Le ciblage de la sous-unité α1 de la pompe à sodium augmente l’effet antitumoral du témozolomide et de l’association bévacizumab–irinotecan dans divers modèles expérimentaux de glioblastomes humains
46. Fluticasone Furoate∗ (FF) Nasal Spray-Development of a Next-Generation Delivery System for Allergic Rhinitis [∗USAN approved name]
47. Once Daily Fluticasone Furoate∗ Nasal Spray (FFNS), a Novel Enhanced Affinity Steroid, Provides 24-hour Relief for the Nasal Symptoms of Perennial Allergic Rhinitis (PAR)
48. PCV82 VALIDATION OF A MODEL TO PREDICT LIFETIME CLINICAL AND ECONOMIC BENEFIT OF RAISING HDL-C IN STATINTREATED PATIENTS WITH PERSISTENTLY LOW HDL-C
49. PCV31 HEALTH ECONOMIC ASSESSMENT OF RAISING HDL-C WITH PROLONGED-RELEASE NICOTINIC ACID (NIASPAN®) WHEN ADDED TO STATIN THERAPY IN PATIENTS WITH DYSLIPIDEMIA AND TYPE 2 DIABETES:AN ANALYSIS FOR SWEDEN
50. Tu-W29:4 Cost-effectiveness of prolonged-release nicotinic acid (NIASPAN® ER) for statin-treated patients at LDL-C goal but remaining at risk due to low HDL-C
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.